From Warren, KD4GUA:
This Sunday we will discuss a blockbuster--THE FDA announced today, Aug. 16, that Warfarin (Coumadin)'s label will carry new information describing the role of genetics in dosing. The label will say that a lower initial warfarin dose "should be considered for patients with certain genetic variations."
This means that to CYA you will need to get a $400 test to determine if that person is a slow absorber or rapid absorber of the drug. Medicare will cover it but private insurance no.
Tune in, should be fun!
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment